

Bibliography

1. Yabroff KR, Wu XC, Negoita S, Stevens J, Coyle L, Zhao J, Mumphrey BJ, Jemal A, Ward KC. Association of the COVID-19 Pandemic With Patterns of Statewide Cancer Services. *J Natl Cancer Inst.* 2022 Jun 13;114(6):907-909.
2. Elshanbary AA, Zaazouee MS, Abdelmonem M, Mohammed YA, Abdel-Aziz W. Risk factors for cardiovascular mortality and melanoma-specific mortality among patients with melanoma: a SEER based study. *Eur J Cancer Prev.* 2022 May 1;31(3):293-300.
3. Neth BJ, Carabenciov ID, Ruff MW, Johnson DR. Temporal Trends in Glioblastoma Survival: Progress then Plateau. *Neurologist.* 2022 May 1;27(3):119-124.
4. Yuan QM, Lin TH, Jin K, Qiu S, Zhou XH, Jin D, Li JK, Yang L, Wei Q. The comparison of survival between active surveillance or watchful waiting and focal therapy for low-risk prostate cancer: a real-world study from the SEER database. *Asian J Androl.* 2022 May-Jun;24(3):305-310.
5. Choi E, Luo SJ, Aredo JV, Backhus LM, Wilkens LR, Su CC, Neal JW, Le Marchand L, Cheng I, Wakelee HA, Han SS. The Survival Impact of Second Primary Lung Cancer in Patients With Lung Cancer. *J Natl Cancer Inst.* 2022 Apr 11;114(4):618-625.
6. Kotha NV, Kumar A, Qiao EM, Qian AS, Voora RS, Nalawade V, Karim Kader A, McKay RR, Stewart TF, Rose BS. Association of Health-Care System and Survival in African American and Non-Hispanic White Patients With Bladder Cancer. *J Natl Cancer Inst.* 2022 Apr 11;114(4):600-608.
7. Allievi N, Goffredo P, Freischlag KW, Utria AF, Cromwell JW, Pisano M, Poiasina E, Hassan I. The "Classification Pendulum" of Stage I Colorectal Cancer: A National Level Analysis of the Survival Difference Between T1 and T2 Colorectal Cancer. *Dis Colon Rectum.* 2022 Apr 1;65(4):505-518.
8. Cranmer LD, Chau B, Mantilla JG, Loggers ET, Pollack SM, Kim TS, Kim EY, Kane GM, Thompson MJ, Harwood JL, Wagner MJ. Is Chemotherapy Associated with Improved Overall Survival in Patients with Dedifferentiated Chondrosarcoma? A SEER Database Analysis. *Clin Orthop Relat Res.* 2022 Apr 1;480(4):748-758.
9. Gulbahce HE, Downs-Kelly E, Herget KA, Stoddard GJ. The 21-Gene Recurrence Score in Special Histologic Subtypes of Breast Cancer. *Arch Pathol Lab Med.* 2022 Apr 1;146(4):478-484.
10. Hutchinson ID, Ata A, DiCaprio MR. Is Metformin Use Associated with Prolonged Overall Survival in Patients with Soft Tissue Sarcoma? A SEER-Medicare Study. *Clin Orthop Relat Res.* 2022 Apr 1;480(4):735-744.
11. Mitchell AP, Mishra Meza A, Panageas KS, Lipitz-Snyderman A, Bach PB, Morris MJ. Real-World Use of Bone-Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer. *J Natl Cancer Inst.* 2022 Mar 8;114(3):419-426.

12. Clarke CA, Patel AV, Kurian AW, Hubbell E, Gomez SL. Racial/Ethnic Differences in Cancer Diagnosed after Metastasis: Absolute Burden and Deaths Potentially Avoidable through Earlier Detection. *Cancer Epidemiol Biomarkers Prev.* 2022 Mar 1;31(3):521-527.
13. Dobyns AC, Coutelle NA, Suthumpong CY, Rodriguez PE, Castro G, Varella MH. Race/ethnicity and advanced stage of renal cell carcinoma in adults: results from surveillance, epidemiology, and end results program 2007-2015. *Eur J Cancer Prev.* 2022 Mar 1;31(2):172-177.
14. Huang C, Hu H, Jia L, Liu H, Hu S. Outcomes of Lymphoma Among American Adolescent and Young Adult Patients Varied by Health Insurance-A SEER-based Study. *J Pediatr Hematol Oncol.* 2022 Mar 1;44(2):e403-e412.
15. Karia PS, Tehranifar P, Visvanathan K, Wright JD, Genkinger JM. Cancer-Specific Mortality in Asian American Women Diagnosed with Gynecologic Cancer: A Nationwide Population-Based Analysis. *Cancer Epidemiol Biomarkers Prev.* 2022 Mar 1;31(3):578-587.
16. Poulson MR, Geary A, Annesi C, Dechert T, Kenzik K, Hall J. The Impact of Income and Social Mobility on Colorectal Cancer Outcomes and Treatment: A Cross-sectional Study. *Ann Surg.* 2022 Mar 1;275(3):546-550.
17. Tadrosse AF, Tadrosse MF, Ezzat BM, Sadek DM, Langer PD. Second Primary Neoplasms in Patients With Sebaceous Carcinoma of the Eyelid: A Population-based Study, 2000 to 2016. *Ophthalmic Plast Reconstr Surg.* 2022 Mar-Apr 1;38(2):193-198.
18. Kuczmarski TM, Jaung T, Mancuso CE, Mozessohn L, Roemer L, Abel GA, Odejide OO. Precancer and cancer-associated depression and anxiety among older adults with blood cancers in the United States. *Blood Adv.* 2022 Feb 22;6(4):1126-1136.
19. Davis Lynn BC, Chernyavskiy P, Gierach GL, Rosenberg PS. Decreasing Incidence of Estrogen Receptor-Negative Breast Cancer in the United States: Trends by Race and Region. *J Natl Cancer Inst.* 2022 Feb 7;114(2):263-270.
20. Li Y, Chen D, Xuan H, Dragomir MP, Calin GA, Meng X, Chen M, Jin H. Construction and validation of prognostic nomogram for metaplastic breast cancer. *Bosn J Basic Med Sci.* 2022 Feb 1;22(1):131-139.
21. Taylor DB, Osazuwa-Peters OL, Okafor SI, Boakye EA, Kuziez D, Perera C, Simpson MC, Barnes JM, Bulbul MG, Cannon TY, Watts TL, Megwalu UC, Varvares MA, Osazuwa-Peters N. Differential Outcomes Among Survivors of Head and Neck Cancer Belonging to Racial and Ethnic Minority Groups. *JAMA Otolaryngol Head Neck Surg.* 2022 Feb 1;148(2):119-127.
22. Wang GM, Cioffi G, Patil N, Waite KA, Lanese R, Ostrom QT, Kruchko C, Berens ME, Connor JR, Lathia JD, Rubin JB, Barnholtz-Sloan JS. Importance of the intersection of age and sex to understand variation in incidence and survival for primary malignant gliomas. *Neuro Oncol.* 2022 Feb 1;24(2):302-310.
23. Guha A, Fradley MG, Dent SF, Weintraub NL, Lustberg MB, Alonso A, Addison D. Incidence, risk factors, and mortality of atrial fibrillation in breast cancer: a SEER-Medicare analysis.

- Eur Heart J. 2022 Jan 31;43(4):300-312.
24. Mahjoub H, Loya A, Ayaz T, Weng CY. Second Primary Malignancies following a Diagnosis of Conjunctival Melanoma. *Curr Eye Res.* 2022 Apr;47(4):634-641. Epub 2022 Jan 27.
 25. Wang J, Tian Y, Huang H, Huang D, Liu Y, Tian Y, Zhu G, Zhang X, Ferris RL. The prognosis of HPV-associated metastatic pharyngeal patients by primary and distant site. *Oral Oncol.* 2022 Feb;125:105675. Epub 2021 Dec 27.
 26. Yang XL, Huang H, Kou LN, Lai H, Chen XP, Wu DJ. Construction and validation of a prognostic model for stage IIIC endometrial cancer patients after surgery. *Eur J Surg Oncol.* 2022 May;48(5):1173-1180. Epub 2021 Dec 27.
 27. Ko EM, Bekelman JE, Hicks-Courant K, Brensinger CM, Kanter GP. Association of gynecologic oncology versus medical oncology specialty with survival, utilization, and spending for treatment of gynecologic cancers. *Gynecol Oncol.* 2022 Feb;164(2):295-303. Epub 2021 Dec 20.
 28. McCusker MG, Mehra R, Amr S, Taylor RJ, Cullen KJ, Goloubeva OG. Comparison of efficacy and toxicity of chemoradiation regimens for head and neck squamous cell carcinoma primary treatment. *Head Neck.* 2022 Mar;44(3):749-759. Epub 2021 Dec 20.
 29. Trabolsi A, Alderuccio JP, Florindez J, Rodriguez G, Saul E, Iyer SG, Chapman JR, Poveda J, Sussman DA, Lossos IS. Marginal zone lymphoma of the colon: case series from a single center and SEER data review. *Leuk Lymphoma.* 2022 May;63(5):1160-1166. Epub 2021 Dec 19.
 30. Wong SM, Ajjamada L, Weiss AC, Prakash I, Skamene S, Boileau JF, Pollak MN, Basik M. Clinicopathologic features of breast cancers diagnosed in women treated with prior radiation therapy for Hodgkin lymphoma: Results from a population-based cohort. *Cancer.* 2022 Apr 1;128(7):1365-1372. Epub 2021 Dec 17.
 31. Zheng C, Luo C, Xie K, Qiang Y, Wang GM, Shen Y. Distinguishing optimal esophagectomy candidates in elderly patients: A nomogram based on propensity score matching. *Eur J Surg Oncol.* 2022 Apr;48(4):909-916. Epub 2021 Dec 16.
 32. Ho WK, Tai MC, Dennis J, Shu X, Li J, Ho PJ, Millwood IY, Lin K, Jee YH, Lee SH, Mavaddat N, Bolla MK, Wang Q, Michailidou K, Long J, Wijaya EA, Hassan T, Rahmat K, Tan VKM, Tan BKT, Tan SM, Tan EY, Lim SH, Gao YT, Zheng Y, Kang D, Choi JY, Han W, Lee HB, Kubo M, Okada Y, Namba S, BioBank Japan Project, Park SK, Kim SW, Shen CY, Wu PE, Park B, Muir KR, Lophatananon A, Wu AH, Tseng CC, Matsuo K, Ito H, Kwong A, Chan TL, John EM, Kurian AW, Iwasaki M, Yamaji T, Kweon SS, Aronson KJ, Murphy RA, Koh WP, Khor CC, Yuan JM, Dorajoo R, Walters RG, Chen Z, Li L, Lv J, Jung KJ, Kraft P, Pharoah PDB, Dunning AM, Simard J, Shu XO, Yip CH, Taib NAM, Antoniou AC, Zheng W, Hartman M, Easton DF, Teo SH. Polygenic risk scores for prediction of breast cancer risk in Asian populations. *Genet Med.* 2022 Mar;24(3):586-600. Epub 2021 Dec 15.
 33. Bao Y, Yang X, Men Y, Kang J, Sun X, Zhao M, Sun S, Yuan M, Ma Z, Hui Z. Postoperative radiotherapy improves survival of patients with ypN2 non-small cell lung cancer after

- neoadjuvant chemotherapy followed by surgery - A propensity score matching study of the Surveillance, Epidemiology, and End Results database. *Thorac Cancer*. 2022 Feb;13(3):404-411. Epub 2021 Dec 14.
34. Du Y, Xu Y. Less extensive surgery for patients with FIGO stage IA2 cervical cancer: A population-based study. *J Gynecol Obstet Hum Reprod*. 2022 Feb;51(2):102291. Epub 2021 Dec 13.
 35. Kim HJ, Kim S, Freedman RA, Partridge AH. The impact of young age at diagnosis (age <40 years) on prognosis varies by breast cancer subtype: A U.S. SEER database analysis. *Breast*. 2022 Feb;61:77-83. Epub 2021 Dec 13.
 36. Fang W, Huang Y, Han X, Peng J, Zheng M. Characteristics of metastasis and survival between male and female breast cancer with different molecular subtypes: A population-based observational study. *Cancer Med*. 2022 Feb;11(3):764-777. Epub 2021 Dec 12.
 37. Eskander MF, Hamad A, Li Y, Fisher JL, Oppong B, Obeng-Gyasi S, Tsung A. From street address to survival: Neighborhood socioeconomic status and pancreatic cancer outcomes. *Surgery*. 2022 Mar;171(3):770-776. Epub 2021 Dec 6.
 38. Yang Z, Shi G. Survival outcomes of combined hepatocellular-cholangiocarcinoma compared with intrahepatic cholangiocarcinoma: A SEER population-based cohort study. *Cancer Med*. 2022 Feb;11(3):692-704. Epub 2021 Dec 4.
 39. Zhu Y, Yang S, He X. Prognostic evaluation models for primary thyroid lymphoma, based on the SEER database and an external validation cohort. *J Endocrinol Invest*. 2022 Apr;45(4):815-824. Epub 2021 Dec 4.
 40. Li Z, Wei J, Cao H, Song M, Zhang Y, Jin Y. Development, validation, and visualization of a web-based nomogram for predicting the incidence of leiomyosarcoma patients with distant metastasis. *Cancer Rep (Hoboken)*. 2022 May;5(5):e1594. Epub 2021 Dec 3.
 41. Jazieh K, Baidoun F, Torrejon N, Merjaneh Z, Saad A, Gad M, Farouk A, Ornstein M, Abraham J. Studying the association between breast cancer and renal cell carcinoma. *Breast Cancer Res Treat*. 2022 Feb;191(3):643-652. Epub 2021 Dec 2.
 42. Lin J, Hu H, Shriver CD, Zhu K. Survival among Breast Cancer Patients: Comparison of the U.S. Military Health System with the Surveillance, Epidemiology and End Results Program. *Clin Breast Cancer*. 2022 Jun;22(4):e506-e516. Epub 2021 Dec 1.
 43. Yang Y, Zheng J, Li Y. Comparison of 4 lymph node staging systems for the prognostic prediction of esophagogastric junction adenocarcinoma with ≤ 15 retrieved lymph nodes. *Eur J Surg Oncol*. 2022 May;48(5):1017-1024. Epub 2021 Dec 1.
 44. Di M, Keeney T, Belanger E, Panagiotou OA, Olszewski AJ. Global Risk Indicator and Therapy for Older Patients With Diffuse Large B-Cell Lymphoma: A Population-Based Study. *JCO Oncol Pract*. 2022 Mar;18(3):e383-e402. Epub 2021 Nov 30.
 45. Relation T, Li Y, Fisher JL, Tsung A, Oppong B, Eskander MF, Obeng-Gyasi S. Inflammatory breast cancer, trimodal treatment, and mortality: Does where you live matter? *Surgery*.

- 2022 Mar;171(3):687-692. Epub 2021 Nov 30.
46. Hu T, Chen Z, Hou M, Lin K. Overall and cancer-specific survival in patients with breast Paget disease: A population-based study. *Exp Biol Med (Maywood)*. 2022 Feb;247(3):187-199. Epub 2021 Nov 29.
 47. Zhang T, Zhu L. Nomogram for predicting postoperative cancer-specific early death in patients with epithelial ovarian cancer based on the SEER database: a large cohort study. *Arch Gynecol Obstet*. 2022 Jun;305(6):1535-1549. Epub 2021 Nov 29.
 48. McClelland PH, Liu T, Ozuner G. Early-Onset Colorectal Cancer in Patients under 50 Years of Age: Demographics, Disease Characteristics, and Survival. *Clin Colorectal Cancer*. 2022 Jun;21(2):e135-e144. Epub 2021 Nov 27.
 49. Ganesh A, Katipally R, Pasquinelli M, Feldman L, Spiotto M, Koshy M. Increased Disparities in Patients Diagnosed with Metastatic Lung Cancer Following Lung CT Screening in the United States. *Clin Lung Cancer*. 2022 Mar;23(2):151-158. Epub 2021 Nov 25.
 50. Quiroz E, Venkateswaran AR, Nelson R, Aldoss I, Pullarkat V, Rego E, Marcucci G, Douer D. Immunophenotype of acute lymphoblastic leukemia in minorities- analysis from the SEER database. *Hematol Oncol*. 2022 Feb;40(1):105-110. Epub 2021 Nov 25.
 51. Taira T, Nozawa H, Kawai K, Sasaki K, Murono K, Emoto S, Kishikawa J, Ozawa T, Yokoyama Y, Abe S, Nagai Y, Anzai H, Sonoda H, Ishihara S. Prognoses in Pathologically Confirmed T1 Lower Rectal Cancer Patients with or without Preoperative Therapy: An Analysis Using the Surveillance, Epidemiology, and End Results Database. *Oncology*. 2022;100(2):82-88. Epub 2021 Nov 24.
 52. Xu MN, Rao Q. Excision Margin and Survival in Patients with High-Risk, Primary Cutaneous Melanoma: A Retrospective Study Based on Surveillance Epidemiology and End Result (SEER) Database. *Dermatology*. 2022;238(3):534-541. Epub 2021 Nov 24.
 53. Liu WH, Lu YN, Sun MT, Nie DH, Han FJ. Trends of Ten Leading Causes of Death in Head and Neck Squamous Cell Carcinoma. *Curr Med Sci*. 2022 Feb;42(1):118-128. Epub 2021 Nov 22.
 54. Liu YL, Cadoo KA, Mukherjee S, Khurram A, Tkachuk K, Kemel Y, Maio A, Belhadj S, Carlo MI, Latham A, Walsh MF, Dubard-Gault ME, Wang Y, Brannon AR, Salo-Mullen E, Sheehan M, Fiala E, Devolder B, Dandiker S, Mandelker D, Zehir A, Ladanyi M, Berger MF, Solit DB, Bandlamudi C, Ravichandran V, Bajorin DF, Stadler ZK, Robson ME, Vijai J, Seshan V, Offit K. Multiple Primary Cancers in Patients Undergoing Tumor-Normal Sequencing Define Novel Associations. *Cancer Epidemiol Biomarkers Prev*. 2022 Feb;31(2):362-371. Epub 2021 Nov 22.
 55. Fu M, Chen Q, Zeng L, Hong T, Zou Q, Yuan Y, Yi W. Prognosis Comparison Between Nipple-Sparing Mastectomy and Total Mastectomy in Breast Cancer: A Case-Control Study After Propensity Score Matching. *Ann Surg Oncol*. 2022 Apr;29(4):2221-2230. Epub 2021 Nov 20.

56. Mukand NH, Ko NY, Nabulsi NA, Hubbard CC, Chiu BC, Hoskins KF, Calip GS. The association between physical health-related quality of life, physical functioning, and risk of contralateral breast cancer among older women. *Breast Cancer*. 2022 Mar;29(2):287-295. Epub 2021 Nov 19.
57. Wagle NS, Park S, Washburn D, Ohsfeldt RL, Rich NE, Singal AG, Kum HC. Racial, Ethnic, and Socioeconomic Disparities in Curative Treatment Receipt and Survival in Hepatocellular Carcinoma. *Hepatol Commun*. 2022 May;6(5):1186-1197. Epub 2021 Nov 19.
58. Yang XL, Guan WJ, Kou LN, Wang MM, Lai H, Wu DJ. A real-world, population-based study of the trends for incidence and prognosis in high-grade neuroendocrine tumor of cervix. *Curr Probl Cancer*. 2022 Apr;46(2):100800. Epub 2021 Nov 19.
59. Zeng X, Peng L, Wen W, Sun W. Comparison of Survival of Patients With T₁₋₂ cN₀ Oropharyngeal Cancer Treated With or Without Elective Neck Dissection. *Laryngoscope*. 2022 Jun;132(6):1205-1212. Epub 2021 Nov 19.
60. Li C, Chen L, Chou C, Ngorsuraches S, Qian J. Using Machine Learning Approaches to Predict Short-Term Risk of Cardiotoxicity Among Patients with Colorectal Cancer After Starting Fluoropyrimidine-Based Chemotherapy. *Cardiovasc Toxicol*. 2022 Feb;22(2):130-140. Epub 2021 Nov 18.
61. Yu AYL, Thomas SM, DiLalla GD, Greenup RA, Hwang ES, Hyslop T, Menendez CS, Plichta JK, Tolnitch LA, Fayanju OM. Disease characteristics and mortality among Asian women with breast cancer. *Cancer*. 2022 Mar 1;128(5):1024-1037. Epub 2021 Nov 18.
62. Chen X, Zhang C, Guo D, Wang Y, Hu J, Hu J, Wang S, Liu X. Distant metastasis and prognostic factors in patients with invasive ductal carcinoma of the breast. *Eur J Clin Invest*. 2022 Apr;52(4):e13704. Epub 2021 Nov 17.
63. Antwi SO, Rabe KG, Bamlet WR, Meyer M, Chandra S, Fagan SE, Hu C, Couch FJ, McWilliams RR, Oberg AL, Petersen GM. Influence of Cancer Susceptibility Gene Mutations and ABO Blood Group of Pancreatic Cancer Proband on Concomitant Risk to First-Degree Relatives. *Cancer Epidemiol Biomarkers Prev*. 2022 Feb;31(2):372-381. Epub 2021 Nov 15.
64. Lu TP, Wu CH, Chang CC, Chan HC, Chattopadhyay A, Lee WC, Chiang CJ, Lee HY, Tien YW. Distinct Survival Outcomes in Subgroups of Stage III Pancreatic Cancer Patients: Taiwan Cancer Registry and Surveillance, Epidemiology and End Results registry. *Ann Surg Oncol*. 2022 Mar;29(3):1608-1615. Epub 2021 Nov 13.
65. Kosiba M, Stolzenbach LF, Collà Ruvolo C, Nocera L, Mansour M, Tian Z, Roos FC, Becker A, Kluth LA, Tilki D, Shariat SF, Saad F, Chun FKH, Karakiewicz PI. Contemporary Trends and Efficacy of Pelvic Lymph Node Dissection at Radical Cystectomy for Urothelial and Variant Histology Carcinoma of the Urinary Bladder. *Clin Genitourin Cancer*. 2022 Apr;20(2):195.e1-195.e8. Epub 2021 Nov 5.
66. Liang M, Chen M, Singh S, Singh S. Prognostic Nomogram for Overall Survival in Small Cell Lung Cancer Patients Treated with Chemotherapy: A SEER-Based Retrospective Cohort

- Study. *Adv Ther.* 2022 Jan;39(1):346-359. Epub 2021 Nov 3.
67. Qi WX, Chen C, Zhao S, Chen J. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for the treatment of locally advanced esophageal cancer: a population-based analysis. *Int J Clin Oncol.* 2022 Feb;27(2):340-347. Epub 2021 Nov 3.
68. Chen Q, Chen J, Huang Z, Zhao H, Cai J. Comparable survival benefit of local excision versus radical resection for 10- to 20-mm rectal neuroendocrine tumors. *Eur J Surg Oncol.* 2022 Apr;48(4):864-872. Epub 2021 Nov 2.
69. Chen JX, Sun JW, Wang Y, Pan T, Zhuang LP, Lin LZ, Lv BC. Lymph node ratio-based the ypTNrM staging system for gastric cancer after neoadjuvant therapy: a large population-based study. *Surg Today.* 2022 May;52(5):783-794. Epub 2021 Nov 1.
70. Corey L, Cote ML, Ruterbusch JJ, Vezina A, Winer I. Disparities in adjuvant treatment of high-grade endometrial cancer in the Medicare population. *Am J Obstet Gynecol.* 2022 Apr;226(4):541.e1-541.e13. Epub 2021 Nov 1.
71. Papageorge MV, de Geus SWL, Woods AP, Ng SC, McAneny D, Tseng JF, Kenzik KM, Sachs TE. The impact of upper gastrointestinal surgical volume on short term pancreaticoduodenectomy outcomes for pancreatic adenocarcinoma in the SEER-Medicare population. *HPB (Oxford).* 2022 Jun;24(6):868-874. Epub 2021 Nov 1.
72. Gao J, Wang S, Li F, Xu H, Li X, Yan L, Zhu L. Nomograms for Predicting Overall Survival and Cancer-Specific Survival of Young Patients with Epithelial Ovarian Cancer: Analysis Based on SEER Program. *Adv Ther.* 2022 Jan;39(1):257-285. Epub 2021 Oct 29.
73. Ragab OM, Mehta S, Nusbaum DJ, Shimada M, Brunette LL, Roman LD, Matsuo K. Incorporation of vaginal brachytherapy to external beam radiotherapy in adjuvant therapy for high-risk early-stage cervical cancer: A comparative study. *Brachytherapy.* 2022 Mar-Apr;21(2):141-150. Epub 2021 Oct 29.
74. Leary DO, Goyal N, Rubin N, Goyal A. Characterization of Primary and Secondary Cutaneous B-Cell Lymphomas: A Population-Based Study of 4758 Patients. *Clin Lymphoma Myeloma Leuk.* 2022 Apr;22(4):e269-e278. Epub 2021 Oct 27.
75. Binder M, Nandakumar B, Rajkumar SV, Kapoor P, Buadi FK, Dingli D, Lacy MQ, Gertz MA, Hayman SR, Leung N, Fonder A, Hobbs M, Hwa YL, Muchtar E, Warsame R, Kourelis TV, Gonsalves WI, Russell S, Lin Y, Siddiqui M, Kyle RA, Dispenzieri A, Kumar SK. Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. *Leukemia.* 2022 Mar;36(3):801-808. Epub 2021 Oct 26.
76. Daskivich TJ, Luu M, Freedland SJ, Sandler H, Spratt DE, Zumsteg ZS. Development and Validation of an Improved Pathological Nodal Staging System in Men with Prostate Cancer. *J Urol.* 2022 Mar;207(3):581-591. Epub 2021 Oct 25.
77. Verstovsek S, Yu J, Scherber RM, Verma S, Dieyi C, Chen CC, Parasuraman S. Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States. *Leuk Lymphoma.* 2022 Mar;63(3):694-702. Epub 2021 Oct 25.

78. Flammia RS, Chierigo F, Würnschimmel C, Horlemann B, Hoeh B, Sorce G, Tian Z, Leonardo C, Tilki D, Terrone C, Saad F, Shariat SF, Montorsi F, Chun FK, Gallucci M, Karakiewicz PI. Survival benefit of chemotherapy in a contemporary cohort of metastatic urachal carcinoma. *Urol Oncol*. 2022 Apr;40(4):165.e9-165.e15. Epub 2021 Oct 20.
79. Yang H, Zeng M, Cao S, Jin L. Nomograms predicting prognosis for locally advanced hypopharyngeal squamous cell carcinoma. *Eur Arch Otorhinolaryngol*. 2022 Jun;279(6):3041-3052. Epub 2021 Oct 14.
80. Zhu J, Xiao W, Li Y. Management of Primary Hepatopancreatobiliary and Ampulla Large Cell Neuroendocrine Carcinoma. *J Laparoendosc Adv Surg Tech A*. 2022 Jun;32(6):639-645. Epub 2021 Oct 11.
81. Wang W, Shen Z, Zhang J, Chen H, Deng X, Peng C, Xie J, Xu Z, Shen B. A Novel Criterion for Lymph Nodes Dissection in Distal Pancreatectomy for Ductal Adenocarcinoma: A Population Study of the US SEER Database. *Ann Surg Oncol*. 2022 Mar;29(3):1533-1539. Epub 2021 Oct 7.
82. Yin L, Wang J, Zhao R, Chen K, Ji Z, Ji G, Zhang X. Comparable long-term survival of patients with colorectal or gastric gastrointestinal stromal tumors treated with endoscopic vs. surgical resection. *Surg Endosc*. 2022 Jun;36(6):4215-4225. Epub 2021 Oct 7.
83. Rice DR, Hyer JM, Tsilimigras D, Pawlik TM. Implications of intensive care unit admissions among medicare beneficiaries following resection of pancreatic cancer. *J Surg Oncol*. 2022 Mar;125(3):405-413. Epub 2021 Oct 5.
84. Zhou M, Thompson TD, Lin HY, Chen VW, Karlitz JJ, Fontham ETH, Theall KP, Zhang L, Hsieh MC, Pollack LA, Wu XC. Impact of Relative Dose Intensity of FOLFOX Adjuvant Chemotherapy on Risk of Death Among Stage III Colon Cancer Patients. *Clin Colorectal Cancer*. 2022 Jun;21(2):e62-e75. Epub 2021 Oct 1.
85. Tan LC, Huang NS, Yu PC, Han PZ, Liu WL, Lu ZW, Shi RL, Shi X, Wang Y, Ji QH, Qu N, Wei WJ, Wang YL. Different clinicopathologic features predispose to different patterns of distant metastasis with heterogeneous short-term prognosis in patients with differentiated thyroid cancer. *Clin Endocrinol (Oxf)*. 2022 Mar;96(3):402-412. Epub 2021 Sep 30.
86. Khan AH, Gao X, Goffredo P, Kahl AR, Utria AF, Charlton ME, Ahad S, Hassan I. Presentation, treatment, and prognosis of colorectal adenosquamous carcinoma: A contemporary analysis of the surveillance, epidemiology, and end results database. *Am J Surg*. 2022 May;223(5):957-962. Epub 2021 Sep 11.
87. Pei JP, Zhao ZM, Sun Z, Gu WJ, Zhu J, Zhu J, Ma SP, Liang Y, Guo R, Zhang R, Zhang CD. Development and validation of a novel classification scheme for combining pathological T stage and log odds of positive lymph nodes for colon cancer. *Eur J Surg Oncol*. 2022 Jan;48(1):228-236. Epub 2021 Sep 9.
88. Wei X, Min Y, Feng Y, He D, Zeng X, Huang Y, Fan S, Chen H, Chen J, Xiang K, Luo H, Yin G, Hu D. Development and validation of an individualized nomogram for predicting the high-

- volume (> 5) central lymph node metastasis in papillary thyroid microcarcinoma. *J Endocrinol Invest*. 2022 Mar;45(3):507-515. Epub 2021 Sep 7.
89. Abt NB, Miller LE, Parikh A, Bhattacharyya N. Insurance Status Effect on Laryngeal Cancer Survival: A Population Based Study. *Ann Otol Rhinol Laryngol*. 2022 Jul;131(7):775-781. Epub 2021 Sep 4.
90. Horlemann B, Würnschimmel C, Hoeh B, Sorce G, Chierigo F, Flammia RS, Tian Z, Saad F, Briganti A, Shariat SF, Galucci M, Chun FKH, Graefen M, Karakiewicz PI. Radical Cystectomy vs. Radiotherapy in Urothelial Bladder Cancer in Elderly and Very Elderly Patients. *Clin Genitourin Cancer*. 2022 Feb;20(1):93.e1-93.e9. Epub 2021 Sep 1.
91. Sabik LM, Eom KY, Dahman B, Li J, van Londen GJ, Bradley CJ. Breast Cancer Treatment Following Health Reform: Evidence From Massachusetts. *Med Care Res Rev*. 2022 Jun;79(3):371-381. Epub 2021 Sep 1.
92. Zhu J, Zheng H, Ge C, Lin H, Yu K, Wu L, Li D, Zhou S, Tang W, Wang Q, Zhang X, Jin X, Xu X, Du J, Fu J. Competing Nomogram for Late-Period Breast Cancer-Specific Death in Patients with Early-Stage Hormone Receptor-Positive Breast Cancer. *Clin Breast Cancer*. 2022 Apr;22(3):e296-e309. Epub 2021 Aug 31.
93. Nocera L, Wenzel M, Collà Ruvolo C, Würnschimmel C, Tian Z, Gandaglia G, Fossati N, Chun FKH, Mirone V, Graefen M, Saad F, Shariat SF, Montorsi F, Briganti A, Karakiewicz PI. The impact of race/ethnicity on upstaging and/or upgrading rates among intermediate risk prostate cancer patients treated with radical prostatectomy. *World J Urol*. 2022 Jan;40(1):103-110. Epub 2021 Aug 26.
94. Wang W, Chang G, Sun Y, Zhuo R, Li H, Hu Y, Ye C. Nomograms for Individualized Evaluation of Prognosis in Adrenocortical Carcinomas for the Elderly: A Population-Based Analysis. *J Invest Surg*. 2022 May;35(5):1153-1160. Epub 2021 Aug 25.
95. Blake EA, Ross MS, Ross ME, Matsuo K, Silverstein ET, Torno LR, Bhargava R, Post MD, Da Silva DM, Taylor S, Walia S, Roman L, McEachron TA. Immunohistochemical analysis of glassy cell carcinoma of the cervix reveals robust lymphocyte infiltrate and the expression of targetable inhibitory immune checkpoints. *Arch Gynecol Obstet*. 2022 Feb;305(2):439-447. Epub 2021 Aug 15.
96. Mukherjee K, Davisson N, Malik S, Duszak R Jr, Kokabi N. National Utilization, Survival, and Costs Analysis of Treatment Options for Stage I Non-Small Cell Lung Cancer: A SEER-Medicare Database Analysis. *Acad Radiol*. 2022 Feb;29 Suppl 2:S173-S180. Epub 2021 Aug 14.
97. Timilsina S, Damato A, Budhathoki N, Grossbard ML, Braunstein M. Characterization of Second Primary Malignancies in Mucosa-Associated Lymphoid Tissue Lymphomas: A SEER Database Interrogation. *Clin Lymphoma Myeloma Leuk*. 2022 Feb;22(2):76-81. Epub 2021 Aug 12.
98. Huang XT, Cai JP, Chen W, Huang CS, Li JH, Gan TT, Liang LJ, Yin XY. Establishment and validation of a nomogram for predicting overall survival of node-negative perihilar

- cholangiocarcinoma. *Asian J Surg*. 2022 Feb;45(2):712-717. Epub 2021 Aug 9.
99. Ladbury C, Liu J, Novak J, Amini A, Glaser S. Age, racial, and ethnic disparities in reported clinical studies involving brachytherapy. *Brachytherapy*. 2022 Jan-Feb;21(1):33-42. Epub 2021 Aug 8.
100. Mukherjee K, Small W Jr, Duszak R Jr. Trends and variations in utilization and costs of radiotherapy for prostate cancer: A SEER medicare analysis from 2007 through 2016. *Brachytherapy*. 2022 Jan-Feb;21(1):12-21. Epub 2021 Aug 8.
101. Weeks KS, Lynch CF, Pagedar N. Trends in Cancer Treatment for Oral Cavity, Oropharynx, and Larynx in 2016 Versus 2009: SEER Patterns of Care Studies. *Ann Otol Rhinol Laryngol*. 2022 Jun;131(6):629-639. Epub 2021 Aug 6.
102. Yan BY, Barilla S, Strunk A, Garg A. Survival differences in acral lentiginous melanoma according to socioeconomic status and race. *J Am Acad Dermatol*. 2022 Feb;86(2):379-386. Epub 2021 Aug 4.
103. Li J, Patil D, Sanda MG, Filson CP. Cancer-specific outcomes for prostate cancer patients who had prebiopsy prostate MRI. *Urol Oncol*. 2022 Feb;40(2):58.e9-58.e15. Epub 2021 Aug 2.
104. Go CC, Kim DH, Go BC, McGeehan B, Briceño CA. Clinicopathologic Characteristics and Prognostic Factors Impacting Survival in Melanoma of the Eyelid. *Am J Ophthalmol*. 2022 Feb;234:71-80. Epub 2021 Jul 31.
105. Xie C, Liao J, Huang C, Wei F, Liu T, Wen W, Sun W. Basaloid squamous cell carcinoma of the hypopharynx: an analysis of 213 cases. *Eur Arch Otorhinolaryngol*. 2022 Apr;279(4):2099-2107. Epub 2021 Jul 28.
106. Gruszczynski NR, Low CM, Choby G, Meister KD, Smith BH, Balakrishnan K. Effects of Social Determinants of Health Care on Pediatric Thyroid Cancer Outcomes in the United States. *Otolaryngol Head Neck Surg*. 2022 Jun;166(6):1045-1054. Epub 2021 Jul 27.
107. Xu L, Chen XK, Xie HN, Wang Z, Qin JJ, Li Y. Treatment and Prognosis of Resectable Cervical Esophageal Cancer: A Population-Based Study. *Ann Thorac Surg*. 2022 Jun;113(6):1873-1881. Epub 2021 Jul 27.
108. Ojinnaka CO, Christ J, Bruening M. Is There a Relationship between County-Level Food Insecurity Rates and Breast Cancer Stage at Diagnosis? *Nutr Cancer*. 2022;74(4):1291-1298. Epub 2021 Jul 23.
109. Wang F, Wang XY, Jiang X. Incidence and risk factors for early mortality in adults with skin Merkel cell carcinoma: A SEER-based study. *J Am Acad Dermatol*. 2022 Feb;86(2):455-458. Epub 2021 Jul 19.
110. Rees HD, Hills NK, Sabnis AJ, Tulpule AB, Shimotake TK, Goldsby RE. Clinical characteristics and outcomes of infants compared with children diagnosed with rhabdomyosarcoma: Analysis of surveillance, epidemiology and end results data from 2000 to 2016. *Cancer Rep (Hoboken)*. 2022 May;5(5):e1503. Epub 2021 Jul 13.

111. Li T, Liu Y, Li J, Zuo M, Cheng Y. Do elderly patients (≥ 75 years old) with glioblastoma benefit from more radical surgeries in the era of temozolomide? *Neurosurg Rev*. 2022 Feb;45(1):741-750. Epub 2021 Jul 9.
112. Gogna S, Samson D, Gachabayov M, Rojas A, Felsenreich DM, Koo D, Gu K, Quintero L, Miller KR, Azim A, Da Eric Dong X. Neuroendocrine neoplasms of the gallbladder: early detection and surgery is key to improved outcome. *Langenbecks Arch Surg*. 2022 Feb;407(1):197-206. Epub 2021 Jul 8.
113. Barbetta A, Goldbeck C, Lim A, Martin SP, Kahn JA, Sheikh MR, Emamaullee J. Treatment and outcomes of hepatocellular carcinoma in patients with Sickle cell disease: a population-based study in the U.S. *HPB (Oxford)*. 2022 Feb;24(2):234-243. Epub 2021 Jul 6.
114. Zhang GJ, Cui YS, Li H. Survival and treatment of cranial and spinal chordomas: a population-based study. *Neurosurg Rev*. 2022 Feb;45(1):637-647. Epub 2021 Jun 22.
115. Luo XD, Han H. Prognostic analysis and nomogram establishment in patients with mucoepidermoid carcinoma of the tongue: a population-based study using the SEER database. *Eur Arch Otorhinolaryngol*. 2022 Mar;279(3):1489-1498. Epub 2021 Jun 21.
116. Breen CT, Chao J, Mehra S, Kohli N. Extranodal Head and Neck Mantle Cell Lymphoma: Characteristics, Treatment, and Survival. *Ann Otol Rhinol Laryngol*. 2022 Apr;131(4):412-419. Epub 2021 Jun 17.
117. Winn AN, Kelly M, Ciprut S, Walter D, Gold HT, Zeliadt SB, Sherman SE, Makarov DV. The cost, survival, and quality-of-life implications of guideline-discordant imaging for prostate cancer. *Cancer Rep (Hoboken)*. 2022 Feb;5(2):e1468. Epub 2021 Jun 17.
118. Osman MH, Mohamed RH, Sarhan HM, Park EJ, Baik SH, Lee KY, Kang J. Machine Learning Model for Predicting Postoperative Survival of Patients with Colorectal Cancer. *Cancer Res Treat*. 2022 Apr;54(2):517-524. Epub 2021 Jun 15.
119. Hoffman RM, Mott SL, McDowell BD, Anand ST, Nepple KG. Trends and practices for managing low-risk prostate cancer: a SEER-Medicare study. *Prostate Cancer Prostatic Dis*. 2022 Mar;25(1):100-108. Epub 2021 Jun 9.
120. Wang Z, Mo C, Chen L, Kong L, Wu K, Zhu Y, Chen X. Application of competing risk model in the prognostic prediction study of patients with follicular thyroid carcinoma. *Updates Surg*. 2022 Apr;74(2):735-746. Epub 2021 Jun 4.
121. Go CC, Kim DH, Briceño CA. A SEER analysis of survival and prognostic factors in merkel cell carcinoma of the head and neck region. *Int J Oral Maxillofac Surg*. 2022 Mar;51(3):314-322. Epub 2021 Jun 3.
122. Liu J, Wang M. Development and validation of nomograms predicting cancer-specific survival of vulvar cancer patients: based on the Surveillance, Epidemiology, and End Results Program. *Int J Gynaecol Obstet*. 2022 Mar;156(3):529-538. Epub 2021 May 27.

123. Liu C, Tian M, Pei H, Tan F, Li Y. Prognostic Value of the N1c in Stage III and IV Colorectal Cancer: A Propensity Score Matching Study Based on the Surveillance, Epidemiology, and End Results (SEER) Database. *J Invest Surg.* 2022 Apr;35(4):850-859. Epub 2021 May 26.
124. Sanchez JI, Shankaran V, Unger JM, Madeleine MM, Espinoza N, Thompson B. Disparities in post-operative surveillance testing for metastatic recurrence among colorectal cancer survivors. *J Cancer Surviv.* 2022 Jun;16(3):638-649. Epub 2021 May 24.
125. Annesi CA, Poulson MR, Mak KS, Tapan U, Dechert TA, Litle VR, Suzuki K. The Impact of Residential Racial Segregation on Non-Small Cell Lung Cancer Treatment and Outcomes. *Ann Thorac Surg.* 2022 Apr;113(4):1291-1298. Epub 2021 May 23.
126. Apaydin EA, Richardson AS, Baxi S, Vockley J, Akinniranye O, Larkin J, Motala A, Hempel S. Differences in lymphoma patients between chimeric antigen receptor T-cell therapy trials and the general population. *Clin Exp Med.* 2022 Feb;22(1):151-155. Epub 2021 May 17.
127. Zhu H, Zhao S, Zhang C, Ji K, Wu W, Yin L, Yan H, Zhou J, Tang R, Miao L. Endoscopic and surgical treatment of T1N0M0 colorectal neuroendocrine tumors: a population-based comparative study. *Surg Endosc.* 2022 Apr;36(4):2488-2498. Epub 2021 May 13.
128. Gerber NK, Shao H, Chadha M, Deb P, Gold HT. Radiation Without Endocrine Therapy in Older Women With Stage I Estrogen-Receptor-Positive Breast Cancer is Not Associated With a Higher Risk of Second Breast Cancer Events. *Int J Radiat Oncol Biol Phys.* 2022 Jan 1;112(1):40-51. Epub 2021 May 8.
129. Xu G, Xiao Y, Hu H, Jin B, Wu X, Wan X, Zheng Y, Xu H, Lu X, Sang X, Ge P, Mao Y, Cai J, Zhao H, Du S. A Nomogram to Predict Individual Survival of Patients with Liver-Limited Metastases from Gastroenteropancreatic Neuroendocrine Neoplasms: A US Population-Based Cohort Analysis and Chinese Multicenter Cohort Validation Study. *Neuroendocrinology.* 2022;112(3):263-275. Epub 2021 Apr 26.
130. Cummings LC, Kou TD, Chak A, Schluchter MD, Margevicius S, Cooper GS. Receipt of Serial Endoscopy Procedures Prior to Esophageal Adenocarcinoma Diagnosis Is Associated with Better Survival. *Dig Dis Sci.* 2022 Mar;67(3):1036-1044. Epub 2021 Apr 21.
131. Collà Ruvolo C, Nocera L, Stolzenbach LF, Wenzel M, Califano G, Tian Z, Verze P, Shariat SF, Saad F, Briganti A, Mirone V, Karakiewicz PI. Tumor Size Predicts Muscle-invasive and Non-organ-confined Disease in Upper Tract Urothelial Carcinoma at Radical Nephroureterectomy. *Eur Urol Focus.* 2022 Mar;8(2):498-505. Epub 2021 Mar 15.
132. Pinheiro LC, Soroka O, Kern LM, Higgason N, Leonard JP, Safford MM. Racial disparities in diabetes care among incident breast, prostate, and colorectal cancer survivors: a SEER Medicare study. *J Cancer Surviv.* 2022 Feb;16(1):52-60. Epub 2021 Mar 4.
133. Gummerson SP, Lowe JT, Taylor KL, Lobo T, Jensen RE. The characteristics of patients who quit smoking in the year following a cancer diagnosis. *J Cancer Surviv.* 2022 Feb;16(1):111-118. Epub 2021 Feb 27.
134. Nocera L, Collà Ruvolo C, Stolzenbach LF, Wenzel M, Tian Z, Larcher A, Capitanio U, Mirone V, Tilki D, Chun FKH, Kapoor A, Shariat SF, Saad F, Montorsi F, Briganti A, Karakiewicz PI.

- Tumor Stage and Substage Predict Cancer-specific Mortality After Nephrectomy for Nonmetastatic Renal Cancer: Histological Subtype-specific Validation. *Eur Urol Focus*. 2022 Jan;8(1):182-190. Epub 2021 Feb 27.
135. Collà Ruvolo C, Würnschimmel C, Wenzel M, Nocera L, Califano G, Tian Z, Shariat SF, Saad F, Chun FKH, Briganti A, Verze P, Imbimbo C, Mirone V, Karakiewicz PI. Comparison between 1973 and 2004/2016 WHO grading systems in patients with Ta urothelial carcinoma of urinary bladder. *J Clin Pathol*. 2022 May;75(5):333-337. Epub 2021 Feb 23.
136. Ayaz T, Fredrickson S, O'Mary K, Panchbhavi MA, Panchbhavi VK. Differences in cancer amputee survival based on marital status: an analysis of the Surveillance, Epidemiology, and End Results (SEER) database. *J Psychosoc Oncol*. 2022;40(2):203-214. Epub 2021 Feb 19.
137. Würnschimmel C, Collà Ruvolo C, Nocera L, Wenzel M, Tian Z, Saad F, Briganti A, Shariat SF, Mirone V, Chun FKH, Tilki D, Graefen M, Karakiewicz PI. Race/Ethnicity Determines Life Expectancy in Surgically Treated T1aN0M0 Renal Cell Carcinoma Patients. *Eur Urol Focus*. 2022 Jan;8(1):191-199. Epub 2021 Feb 18.
138. Cheng N, Farley J, Qian J, Zeng P, Chou C, Hansen R. The association of continuity of care and risk of mortality in breast cancer patients with cardiometabolic comorbidities. *J Psychosoc Oncol*. 2022;40(2):184-202. Epub 2021 Jan 18.
139. Hu T, You S. Overall and Cancer-Specific Survival in Patients With Renal Pelvic Transitional Cell Carcinoma: A Population-Based Study. *Front Med (Lausanne)*. 2022 Jan 3;8:719800. doi: 10.3389/fmed.2021.719800. eCollection 2021.
140. Hu Z, Zuo Z, Miao H, Ning Z, Deng Y. Incidence, Risk Factors and Prognosis of T4a Gastric Cancer: A Population-Based Study. *Front Med (Lausanne)*. 2022 Jan 5;8:767904. doi: 10.3389/fmed.2021.767904. eCollection 2021.
141. Li W, Dong S, Wang B, Wang H, Xu C, Zhang K, Li W, Hu Z, Li X, Liu Q, Wu R, Yin C. The Construction and Development of a Clinical Prediction Model to Assess Lymph Node Metastases in Osteosarcoma. *Front Public Health*. 2022 Jan 6;9:813625. doi: 10.3389/fpubh.2021.813625. eCollection 2021.
142. Ryan C, Stoltzfus KC, Horn S, Chen H, Louie AV, Lehrer EJ, Trifiletti DM, Fox EJ, Abraham JA, Zaorsky NG. Epidemiology of bone metastases. *Bone*. 2022 May;158:115783. Epub 2020 Dec 1.
143. Brewster R, Deb S, Pendharkar AV, Ratliff J, Li G, Desai A. The effect of socioeconomic status on age at diagnosis and overall survival in patients with intracranial meningioma. *Int J Neurosci*. 2022 Apr;132(4):413-420. Epub 2020 Sep 10.
144. Yang Z, Bai Y, Liu M, Hu X, Han P. Development and Validation of Prognostic Nomograms to Predict Overall and Cancer-Specific Survival for Patients with Adenocarcinoma of the Urinary Bladder: A Population-Based Study. *J Invest Surg*. 2022 Jan;35(1):30-37. Epub 2020 Aug 27.

145. Younis MH, Summers S, Pretell-Mazzini J. Bone metastasis in extremity soft tissue sarcomas: risk factors and survival analysis using the SEER registry. *Musculoskelet Surg.* 2022 Mar;106(1):59-68. Epub 2020 Jul 7.
146. Zhang XF, Xue F, Wu Z, Lopez-Aguilar AG, Poultsides G, Makris E, Rocha F, Kanji Z, Weber S, Fisher A, Fields R, Krasnick BA, Idrees K, Smith PM, Cho C, Beems M, Lyu Y, Maithel SK, Pawlik TM. Development and Validation of a Modified Eighth AJCC Staging System for Primary Pancreatic Neuroendocrine Tumors. *Ann Surg.* 2022 Jun 1;275(6):e773-e780. Epub 2020 Jun 3.
147. Xu G, Cui P, Zhang C, Lin F, Xu Y, Guo X, Cai J, Baklaushev VP, Peltzer K, Chekhonin VP, Wang X, Wang G. Racial disparities in bone metastasis patterns and targeted screening and treatment strategies in newly diagnosed lung cancer patients. *Ethn Health.* 2022 Feb;27(2):329-342. Epub 2020 Mar 28.